These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 11876575

  • 1. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A, Belpaire FM.
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [Abstract] [Full Text] [Related]

  • 2. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH.
    Clin Pharmacokinet; 1997 Feb; 32 Suppl 1():1-21. PubMed ID: 9068931
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P.
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [Abstract] [Full Text] [Related]

  • 4. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L, Riesenman C, Lam YW.
    Clin Pharmacokinet; 1995 Dec; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [Abstract] [Full Text] [Related]

  • 5. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
    Caccia S.
    Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
    [Abstract] [Full Text] [Related]

  • 6. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE, Ahern D, Scatina J, Kao J.
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.
    Lane RM.
    Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():31-61. PubMed ID: 9032002
    [Abstract] [Full Text] [Related]

  • 8. Differences in interactions of SSRIs.
    Brøsen K.
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [Abstract] [Full Text] [Related]

  • 9. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA, Naranjo CA, Brenmer KE, Hassan PC.
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C, Härtter S.
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [Abstract] [Full Text] [Related]

  • 11. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E, Santoro V, D'Arrigo C.
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [Abstract] [Full Text] [Related]

  • 12. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P, Rochat B.
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [Abstract] [Full Text] [Related]

  • 13. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K.
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [Abstract] [Full Text] [Related]

  • 14. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K.
    Eur J Clin Pharmacol; 1996 Mar; 51(1):73-8. PubMed ID: 8880055
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
    Richelson E.
    Mayo Clin Proc; 1997 Sep; 72(9):835-47. PubMed ID: 9294531
    [Abstract] [Full Text] [Related]

  • 16. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
    Luong TT, Powers CN, Reinhardt BJ, Weina PJ.
    Curr Res Pharmacol Drug Discov; 2022 Sep; 3():100112. PubMed ID: 35756846
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
    Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI.
    Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
    [Abstract] [Full Text] [Related]

  • 18. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
    Rasmussen BB, Brøsen K.
    Ther Drug Monit; 2000 Apr; 22(2):143-54. PubMed ID: 10774624
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacokinetics and drug interactions of antidepressive agents].
    Sawada Y, Ohtani H.
    Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
    [Abstract] [Full Text] [Related]

  • 20. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
    Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J.
    J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.